Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity by Hughes Dyfrig A, Vilar F Javier, Ward Charlotte C, Alfirevic Ana, Park B Kevin, Pirmohamed Munir in Pharmacogenetics (2004). PubMed

Abstract

Abacavir, a human immunodeficiency virus-1 (HIV-1) nucleoside-analogue reverse transcriptase inhibitor, causes severe hypersensitivity in 4-8% of patients. HLA B*5701 is a known genetic risk factor for abacavir hypersensitivity in Caucasians. Our aim was to confirm the presence of this genetic factor in our patients, and to determine whether genotyping for HLA B*5701 would be a cost-effective use of healthcare resources.

[ hide abstract ]

Discussed In Paper

Variant Annotations

Sign in to see variant annotations.